Vaccines Today—March 6, 2026

This weekly update in vaccines highlights key developments across regulatory decisions, clinical trial results, vaccine strain guidance, product launches, and strategic industry agreements shaping the global vaccine landscape.

In Today’s Newsletter

Dive deeper

💉 EMA backs first combined COVID-19 + influenza vaccine (mCombriax) [1] [EU • 27 Feb 2026]

https://www.ema.europa.eu/en/news/first-combined-covid-19-influenza-vaccine-people-50-years-older
Context: Pivotal study (~8,000 participants ≥50) showed antibody responses non-inferior to separate Spikevax plus standard influenza vaccines.
Key point: mCombriax (Moderna; mRNA COVID-19 + influenza vaccine) received a positive opinion from the European Medicines Agency CHMP for adults ≥50 years.
Implication: May streamline seasonal vaccination if approved, combining two respiratory vaccines into one shot.

🦟 India advances DengiAll single-dose dengue vaccine trial [2] [India • 27 Feb 2026]

https://www.independent.co.uk/bulletin/news/dengue-fever-vaccine-india-b2928985.html
Context: Investigational single-dose vaccine uses a weakened dengue strain developed by the US NIH; participants followed for two years (efficacy endpoints not specified).
Key point: DengiAll (Panacea Biotec; tetravalent dengue vaccine) entered Phase 3 trials across India with >10,000 participants.
Implication: Signals pipeline investment in dengue prevention and potential expansion of global vaccine options.

🧪 4CMenB meningococcal vaccine shows no gonorrhea protection in RCT [3] [27 Feb 2026]

https://www.cidrap.umn.edu/gonorrhea/meningococcal-b-vaccine-fails-prevent-gonorrhea-trial-finds
Context: Trial enrolled 587 participants with recent STI history; results differ from earlier observational studies suggesting partial cross-protection.
Key point: GoGoVax randomized trial found the 4CMenB meningococcal B vaccine did not reduce gonorrhea incidence versus placebo in high-risk men.
Implication: Observational signals may not translate to causal protection, reinforcing the need for randomized evidence.

🌍 WHO updates influenza vaccine strains for 2026–2027 season [4] [27 Feb 2026]

https://www.who.int/news/item/27-02-2026-recommendations-for-influenza-vaccine-composition-for-the-2026-2027-northern-hemisphere-season
Context: Season dominated by influenza A, including an emerging A(H3N2) variant; B/Yamagata lineage viruses have not been detected since 2020.
Key point: WHO recommended updated strains for Northern Hemisphere influenza vaccines following global surveillance review.
Implication: Guides annual vaccine reformulation to improve strain match with circulating viruses.

🫁 Capvaxive 21-valent pneumococcal vaccine launches in South Korea [5] [South Korea • 03 Mar 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=30787
Context: STRIDE trials showed strong immunogenicity for serotypes unique to Capvaxive and non-inferiority for shared serotypes versus earlier vaccines.
Key point: Capvaxive (Merck/MSD; 21-valent pneumococcal conjugate vaccine) launched for adults ≥18 to prevent invasive pneumococcal disease and pneumonia.
Implication: Introduces additional serotype coverage that may influence adult pneumococcal vaccination strategies.

👶 Modeling study finds PCV20 most cost-effective pediatric pneumococcal strategy [6] [US • 03 Mar 2026]

https://www.drugtopics.com/view/new-data-suggests-pcv20-is-the-most-cost-effective-choice-for-pediatric-pneumococcal-prevention
Context: Dynamic transmission model estimated large reductions in invasive disease, pneumonia, and otitis media over a 10-year horizon.
Key point: Modeling analysis projects PCV20 (Prevnar 20; Pfizer) prevents more pneumococcal disease cases than PCV15 or PCV13 in US pediatric programs.
Implication: Could inform payer discussions and guideline decisions on pediatric pneumococcal vaccine selection.

⚖️ Moderna settles mRNA lipid nanoparticle patent dispute [7] [03 Mar 2026]

https://feeds.issuerdirect.com/news-release.html?newsid=5178901572623640&symbol=MRNA
Context: Agreement includes a $950 million payment and a license covering Moderna’s infectious disease pipeline; litigation will end if appeals resolve.
Key point: Moderna reached a global settlement with Arbutus Biopharma and Genevant Sciences over lipid nanoparticle technology used in mRNA vaccines.
Implication: Removes legal uncertainty around key mRNA platform technologies.

🧬 Serum Institute wins approval for COVID-flu combination vaccine Phase 3 trial [8] [India • 03 Mar 2026]

https://www.livemint.com/news/india-drug-regulator-approves-combined-covid-influenza-vaccine-trials-serum-institute-11772528169120.html
Context: The CIC and tNIV vaccines aim to deliver dual respiratory protection in a single shot; regulator also cleared rollout of a JN.1-targeted COVID booster.
Key point: India’s CDSCO approved Phase 3 trials for Serum Institute of India’s COVID-19 + influenza combination vaccine candidates.
Implication: Signals growing global interest in combination respiratory vaccines to simplify immunization schedules.

Why it matters

Combination vaccines targeting COVID-19 and influenza are emerging globally, potentially simplifying adult immunization campaigns.
Updated WHO strain recommendations will guide manufacturing for the next Northern Hemisphere influenza season.
Randomized evidence clarifies that 4CMenB should not be used for gonorrhea prevention, correcting earlier observational assumptions.
Expanded pneumococcal vaccine options, including Capvaxive and PCV20, continue to reshape adult and pediatric prevention strategies.
Resolving key mRNA platform patent disputes may reduce uncertainty for developers pursuing next-generation vaccines.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Vaccines archive on our research hub page.

FAQ

What is mCombriax and who may receive it?

mCombriax (Moderna) is an mRNA vaccine designed to protect against both COVID-19 and seasonal influenza. EMA’s CHMP recommended it for adults aged 50 years and older, pending final European Commission authorization. [1]

How does DengiAll differ from other dengue vaccines?

DengiAll (Panacea Biotec) is an investigational single-dose tetravalent dengue vaccine intended to protect against all four dengue serotypes. Current global options include Qdenga and Dengvaxia, which have different dosing schedules or eligibility constraints. [2]

Does the meningococcal B vaccine prevent gonorrhea?

The GoGoVax randomized trial found that 4CMenB did not reduce gonorrhea incidence versus placebo in the study population, despite earlier observational studies suggesting possible cross-protection. [3]

Why does WHO update influenza vaccine strains each year?

WHO reviews global influenza surveillance data twice annually to recommend vaccine strains that best match circulating viruses. Manufacturers use these recommendations when producing seasonal vaccines. [4]

What is Capvaxive used for?

Capvaxive (Merck/MSD) is a 21-valent pneumococcal conjugate vaccine designed to protect adults against invasive pneumococcal disease and pneumonia by targeting a broader set of pneumococcal serotypes. [5]

Entities / Keywords

mCombriax (Moderna), Spikevax, DengiAll (Panacea Biotec), 4CMenB meningococcal B vaccine, GoGoVax trial, WHO influenza strain selection, Capvaxive (Merck/MSD; V116), PCV20 (Prevnar 20; Pfizer), Arbutus Biopharma, Genevant Sciences, Serum Institute of India CIC vaccine,